Objective To analyze the clinical efficacy of empagliflozin in patients with chronic heart failure with reduced ejection fraction(HFrEF)combined with type 2 diabetes mellitus(T2DM).Methods A total of 100 patients with chronic heart failure with type 2 diabetes mellitus and reduced ejection fraction were retrospectively collected from June 2020 to December 2022 in the Department of Cardiovascular Medi-cine,Zhongshan Huangpu People's Hospital.All patients took 10 mg/d of empagliflozin tablets and took other drugs before the sample was included.The cardiac function indexes and laboratory indexes of the pa-tients before the test,3 months and 6 months were observed.Results The cardiac function and laboratory indexes of patients with chronic HFrEF combined with T2DM were improved after 3 months of treatment with empagliflozin(P<0.05),and the improvement was more obvious after 6 months of treatment than after 3 months of treatment(P<0.05).Conclusion Patients with chronic HFrEF combined with T2DM were treated with empagliflozin to enhance cardiac function and improve laboratory indicators,which confirmed the efficacy and of empagliflozin in the treatment of the disease.
关键词
2型糖尿病/慢性射血分数降低性心力衰竭/心功能/三酰甘油
Key words
Type 2 diabetes mellitus/Chronic heart failure with reduced ejection fraction/Cardiac function/Triac-ylglycerol
维普
万方数据